Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77675 | 0.89 | ALDH1A1 (0.64) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9527373 | 0.84 | ALDH1A1 (0.67) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL76730 | 0.81 | ALDH1A1 (0.64) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL10579958 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL10577576 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL30932257 | 0.79 | CYP11B1 (0.67) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL28206073 | 0.79 | CYP11B1 (0.67) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL9665076 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL9523915 | 0.78 | ALDH1A1 (0.82) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 | |
| SCHEMBL10581105 | 0.78 | ALDH1A1 (0.63) | ALDH1A1CYP19A1LMNASMN1; SMN2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1022184-C | Process for preparing (1 H-imidzol-1-ylmethyl) substituted benzotriazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1993-09-22 | — | — | CN | disclosed |
| EP-0293978-B1 | (1H-AZOL-1-YLMETHYL)SUBSTITUTED BENZOTRIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-15 | — | — | EP | disclosed |
| CN-1020903-C | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THE PREPARATION THEREFOR | JANSSEN PHARMACEUTICA NV (BE) | 1993-05-26 | — | — | CN | disclosed |
| EP-0260744-B1 | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| US-5039677-A | Estrogen inhibitor | JANSSEN PHARMACEUTICA N.V. (CA) | 1991-08-13 | — | — | US | disclosed |
| US-4943574-A | AROMATASE INHIBITORS, ESTROGEN DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-24 | — | — | US | disclosed |
| US-4859684-A | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-22 | — | — | US | disclosed |
| CN-88103408-A | Process for preparing (1H-oxazol-1-ylmethyl) substituted benzotriazole derivatives | — | 1988-12-14 | — | — | CN | disclosed |
| CN-87106423-A | Novel (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and process for their preparation | — | 1988-04-20 | — | — | CN | disclosed |
| EP-0260744-A2 | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-03-23 | — | — | EP | disclosed |